Market Overview

Heat Biologics Cools Off, Bluebird Bio Heats Up

Heat Biologics Cools Off, Bluebird Bio Heats Up
Related BLUE
Vetr Crowd Upgrades Bluebird After Trump Presser
The Year's Biggest Healthcare Conference Commences This Week; Here's What You Need To Know
Related CELG
Orphan Drugs Among 2015's Top 10 Best-Selling Medications
Oppenheimer Upgrades Agios Pharma On Expectations For First Drug Launch
TheStreet's Feuerstein says Celgene should gobble up Biogen (Seeking Alpha)

In a classic example of how trial results can impact stock prices, shares of Heat Biologics Inc (NASDAQ: HTBX) plunged 58 percent in the Thursday’s pre-market hours following a negative outcome of its bladder cancer study, while bluebird bio Inc (NASDAQ: BLUE)’s impressive early cancer studies propelled the stock by 22 percent.

The Trials

Heat Biologics said its phase 2 trial of Vesigenurtacel-L (HS-410) in combination with BCG in patients with non-muscle invasive bladder cancer (NMIBC) failed to meet primary endpoint. The primary endpoint was proportion of recurrence-free survival at one year between the vaccine and placebo arms of the trial.

the other hand, bluebird bio said early data from its ongoing Phase 1 study of bb2121 showed objective anti-tumor responses in heavily pre-treated multiple myeloma patients. bluebird bio is developing bb2121 in collaboration with Celgene Corporation (NASDAQ: CELG).

Recent Stock Performance

Shares of Durham, North Carolina-based Heat Biologics closed Wednesday’s trading at $2.87, while bluebird bio ended trading at $60.35.

In the pre-market hours Thursday, Heat Biologics sank 58 percent to $1.20, while Cambridge, Massachusetts-based bluebird bio surged 22.54 percent to $73.95. Shares of Celegene too gained 1.6 percent to $120.45 on the news.

Posted-In: bb2121Biotech News Health Care FDA Movers Trading Ideas General Best of Benzinga


Related Articles (CELG + BLUE)

View Comments and Join the Discussion!